EURORDIS recognises Orphan Europe and Swedish Orphan Biovitrum (SOBI) with awards
Authored by Karl Simpson
Novimmune sees immunotherapy and orphan focus attract new capital
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged acute lymphocytic leukemia, Alexion, Angel investment, Ariad, bioValley, Covagen, Crohn's disease, Dr Jonathan hepple, Geneva, Hemophagocytic lymphohistiocytosis, Lomard odier ventures, Merck Serono, monoclonoal antibody therapeutics, NovImmune, Nyon, Rare Disease, renal allograft transplantation, Rosetta Capital, Shire, Switzerland, Vertex Pharmaceuticals, Zug
Leave a comment
David Roth appointed Chief Medical Officer of Infinity
Authored by Karl Simpson
Posted in Executive Appointments, Orphan Drugs and Rare Diseases
Tagged Boston Biotech, Chief Medical Officer, chronic myelogenous leukemia, clinical development, CMO, David Roth, haemophilia A, Harvard, He, Infinity Pharmaceuticals, Julian Adams, Massachusetts Institutue of Technology, Medical Affairs, Pfizer, Senior Vice President, Wyeth
Leave a comment
Karolinska Development announces new Chief Financial Officer
Authored by Karl Simpson
Posted in Executive Appointments, Pharmaceutical business
Tagged Aprea AB, Bernd Seizinger, BMS, Bristol-Myers Squibb, CFO, Chief Financial Officer, Christian Tange, CMC Biologics, Copenhagen Business School, Karolinska Development, Martin Welschof, Medicon Valley, oncology, Opsona Therapeutics, Stockholm, sweden
Leave a comment
New Enterprise Associates backs veteran rare diseases executive team
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Boston Biotech, Cristina Csimma, Cydan Corporation, FDA, Jon Saxe, KLS Partners, LUM-001, Lumos Pharma, NEA, New England Associates, Orphan drugs, Prosensa, Rare Disease, Rick Hawkins, Sante Ventures, unmet medical needs
Leave a comment
Kiadis rides high after positive clinical data
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged 4SC, acute lymphoblastic leukaemia, Acute Myeloid Leukaemia, ALL, Alta Partners, AML, Amsterdam Biotech, ATIR, Cardion, clinical data, Dr Manfred Rudiger, Dutch, Esprit Capital, haematology, holland, Igenon, Kiadis, Life Science Partners, MDS, MedSciences Capital, myelodysplastic syndome, oncology, Orphan Drug, phase II study, t2cure
Leave a comment
Biosimilars – is global development a reality?
Posted in Pharmaceutical business
Tagged animal studies, Biologicals Advice Limited, Biosimilar Medicines Working Party, biosimilars, CHMP, Committee for Advanced Therapies, Committee for Medicine Products for Human Use, comparator, development, Dr Narayanan, EMA, erythropoietin, europe, filgrastim, Gene Therapy Working Party, infliximab, regulatory affairs, somatropin
Leave a comment
Amal Therapeutics raises seed funding for cancer immunotherapy
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amal Therapeutics, bioValley, BIVF, Boehringer Ingelheim, Cancer immunotherapy, Dr Knut Elbers, High-Tech Grunderfonds, HTGF, Madiha Derouazi, multi-epitopic cellular immune response targeting cancer cells, oncology, University of Geneva
Leave a comment
